The European Patent Office (EPO) has officially granted patent EP3077503B1, titled 'METHOD AND COMPOSITION FOR INDUCING CHONDROGENESIS OR TENOGENESIS IN MESENCHYMAL STEM CELLS'. The patent, designated with publication kind B1, was published on March 18, 2026. This grant is associated with International Patent Classifications C12N 5/077 and C12N 5/0775, indicating its focus on cell culture technologies, specifically for inducing chondrogenesis or tenogenesis in mesenchymal stem cells.

This patent grant signifies the formal recognition of intellectual property rights for the described invention within the designated European states. While this is a patent grant and not a regulatory rule imposing direct compliance obligations, it is crucial for companies operating in the biotechnology and pharmaceutical sectors, particularly those involved in regenerative medicine or stem cell therapies. Companies should review this patent to ensure their own research, development, or commercial activities do not infringe upon the granted claims. The designated states listed indicate the geographical scope of the patent protection.